GlassScriptPhysician profile
Brandon Curtis Howe
NPI 1255911723
$1,602.45
in general payments reported to CMS, 2019-2025
20 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what 96% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $335 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,585.07 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $333.80 | 2024-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $207.86 | 2024-2025 | Nucala, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $140.80 | 2024-2025 | Zerbaxa, Winrevair |
| Olympus America INC. | $130.42 | 2025 | Spiration Valve System, Single-Use Flexible Video Bronchoscope |
| Actelion Pharmaceuticals US, INC. | $125.71 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $102.83 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.33 | 2024-2025 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $76.76 | 2024-2025 | Glassia |
| Alexion Pharmaceuticals, INC. | $58.75 | 2025 | Ultomiris |
| Inspire Medical Systems, INC. | $57.97 | 2025 | Inspire |
| Insmed, INC. | $56.42 | 2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $50.06 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $30.72 | 2025 | Terlivaz |
| Tempus Ai, INC | $28.63 | 2025 | Xt Cdx |
| Inogen, INC. | $21.09 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $20.29 | 2025 | Zevtera |
| Ars Pharmaceuticals Operations, INC. | $19.74 | 2025 | Neffy |
| Paratek Pharmaceuticals, INC. | $17.34 | 2024 | Nuzyra |
| Verona Pharma, INC. | $16.14 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $14.79 | 2025 | Phesgo, Tecentriq, Polivy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Howe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.